Le marché du traitement de l'hématurie devrait atteindre 1 103,61 millions de dollars US d'ici 2028, contre 932,89 millions de dollars US en 2021 ; il devrait croître à un TCAC de 2,4 % de 2021 à 2028.
L'hématurie est une condition médicale indiquée par la présence de sang dans l'urine ; dans des circonstances normales, l'urine ne contient pas de globules rouges. Cela peut entraîner de graves problèmes pouvant également causer des calculs rénaux, une infection des voies urinaires et d'autres maladies héréditaires. Des facteurs tels que la prévalence élevée des indications associées à l'hématurie, la sensibilisation croissante aux options de traitement et l'amélioration des dépenses de santé stimulent le marché. Cependant, les cas non diagnostiqués d'indications associées qui entravent l'efficacité du traitement freinent la croissance du marché du traitement de l'hématurie. En outre, la portée croissante des traitements connexes devrait offrir des opportunités de croissance importantes aux acteurs du marché du traitement de l'hématurie pour élargir leur clientèle, en particulier dans les pays en développement.
Aperçus stratégiques
L'Europe a connu une croissance exponentielle du nombre de cas de COVID-19 en 2020. L'Espagne, l'Allemagne, la France, l'Italie et le Royaume-Uni sont les pays les plus touchés de la région. La protéinurie et l'hématurie auraient une prévalence plus élevée chez les patients COVID-19 que chez les patients atteints d'IRA. Des études rétrospectives en Chine ont rapporté que la protéinurie et l'hématurie sont observées chez les patients COVID-19, et les conditions également associées à une mortalité plus élevée. Selon la base de données COVID-19 de l'Association européenne du rein (ERACODA), établie en mars 2020, environ 25 % des patients transplantés rénaux reçoivent un diagnostic de SRAS-CoV-2. Par conséquent, les patients positifs au COVID sont également plus susceptibles de recevoir des traitements contre les maladies rénales.
Régions lucratives pour le marché du traitement de l'hématurie
Aperçu du marché
La forte prévalence des indications associées à l'hématurie alimente la croissance du marché du traitement de l'hématurie
Rein chronique (CKD) est une maladie courante et potentiellement mortelle qui affecte une plus grande population dans le monde. Il existe différents types d'IRC, tels que les calculs rénaux, la glomérulonéphrite, la polykystose rénale et les infections des voies urinaires. L'IRC est l'une des principales causes de la prévalence de l'hématurie. Par exemple, selon une étude publiée dans le National Center for Biotechnology Information en mai 2019, les infections des voies urinaires (IVU) sont généralement observées en tant qu'infections ambulatoires aux États-Unis, survenant principalement chez les femmes du groupe d'âge entre 14 et 24 ans. De plus, la prévalence des infections urinaires chez les femmes de plus de 65 ans est d'environ 20 % par rapport à la population générale, qui est d'environ 11 %. Actuellement, le marché mondial du traitement de l'hématurie bénéficie de manière significative de la prévalence croissante des indications associées. En Amérique du Nord, les États-Unis sont le plus grand marché pour le marché du traitement de l'hématurie. La croissance de ce marché est principalement tirée par la prévalence croissante des maladies rénales chroniques (CKD) et le nombre croissant de lancements de produits par des acteurs clés. Par exemple, en 2016, les Centers for Disease Control and Prevention (CDC) ont déclaré qu'environ 0,7 million de personnes étaient traitées pour une insuffisance rénale terminale (IRT) aux États-Unis. La prévalence de l'IRT a plus que doublé entre 1990 et 2016. De plus , l'augmentation de l'incidence de l'hématurie chez les adultes, la sensibilisation accrue, les activités de recherche et développement approfondies devraient également stimuler la prévalence des traitements de l'hématurie, ce qui offrira à terme une opportunité lucrative pour la croissance du marché. L'augmentation de la population gériatrique est également l'un des principaux moteurs de ce marché, car le vieillissement est le principal facteur de risque responsable de l'incidence croissante des maladies rénales. Par exemple, selon une étude publiée par le Population Reference Bureau en 2020, la population âgée de 65 ans aux États-Unis devrait doubler d'ici 2060.
Treatment-Based Insights
Le Le marché du traitement de l'hématurie, basé sur le traitement, est segmenté en médicaments, thérapies et autres. Comme l'hématurie est associée à diverses indications telles que les infections urinaires, les calculs rénaux, le cancer du sang, les calculs de la vessie et le cancer de la prostate, les médicaments utilisés pour ces indications peuvent également être utilisés pour son traitement. L'alfuzosine, la ciprofloxacine, la doxazosine, l'ibuprofène et la tamsulosine font partie des médicaments couramment utilisés pour le traitement de l'hématurie. Il s'agit d'un type de traitement préféré car les médicaments peuvent être administrés à domicile et dans les établissements de santé.
Marché du traitement de l'hématurie, par traitement - 2020 et 2028
Aperçus basés sur les indications
Le marché du traitement de l'hématurie, basé sur l'indication, est segmenté en calculs rénaux, infections des voies urinaires (IVU), urétrite, cancer du sang, calculs vésicaux, cancer de la prostate, cystite, traumatisme, exercice vigoureux, maladie rénale polykystique, endométriose et menstruation. En 2021, le segment des infections urinaires devrait détenir la plus grande part de marché. De plus, le marché du traitement de l'hématurie pour le segment de l'urétrite devrait également enregistrer le TCAC le plus rapide de 3,1 % de 2021 à 2028.
Insights basés sur le type
Le marché du traitement de l'hématurie, basé sur type, a été segmenté en hématurie macroscopique, hématurie microscopique, hématurie idiopathique et hématurie du jogger. Le segment de l'hématurie macroscopique devrait détenir la plus grande part du marché en 2021. Cependant, le segment de l'hématurie microscopique devrait enregistrer le TCAC le plus élevé du marché au cours de la période de prévision.
End User-Based Insights
Le marché du traitement de l'hématurie, basé sur l'utilisateur final, est segmenté en hôpitaux, cliniques, centres de chirurgie ambulatoire (ASC) et autres. En 2021, le segment des hôpitaux devrait détenir la plus grande part du marché. En outre, le segment des cliniques devrait également connaître une croissance de sa demande au TCAC le plus rapide de 6,9 % de 2021 à 2028.
Les entreprises opérant sur le marché du traitement de l'hématurie adoptent la stratégie d'innovations de traitement pour répondre à l'évolution de la clientèle. demandes à travers le monde, ce qui leur permet également de maintenir leur marque sur le marché mondial.
Marché du traitement de l'hématurie - par traitement
- Médicaments
- Thérapies
- Autres
Marché du traitement de l'hématurie - par indication
- Infections des voies urinaires
- Calculs rénaux
- Urétrite
- Cancer du sang
- Cancer de la prostate
- Cystite, traumatisme
- Exercice vigoureux
- Maladie polykystique des reins
- Endométriose
- Menstruation
< li class="Bullet1-TIPCxSpMiddle">Pierres vésicales
Marché du traitement de l'hématurie - par type
- Hématurie macroscopique
- Hématurie microscopique
- Hématurie idiopathique
- Hématurie de Jogger
Marché du traitement de l'hématurie - par utilisateur final
- Hôpitaux
- Cliniques
- ASC’s
- Autres
Marché du traitement de l'hématurie - par géographie
- Amérique du Nord
- États-Unis
- Canada
- Mexique
- Europe
- France
- Allemagne
- Italie
- Royaume-Uni
- Espagne
- Reste de l'Europe
- Asie-Pacifique (APAC)
- Chine
- Inde
- Corée du Sud
- Japon
- Australie
- Reste de l'APAC
- Moyen-Orient et Afrique (MEA)
- Afrique du Sud
- Arabie saoudite
- EAU
- Reste du MEA
- Amérique du Sud et centrale (SCAM)
- Brésil
- Argentine
- Reste de la SCAM
Profils des entreprises
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
li>
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Hematuria is the presence of blood in the urine. Gross or visible hematuria occurs when the urine is red or pink, indicating the presence of blood in the urine. Blood can sometimes be found in the urine but is difficult to see; this is known as microscopic hematuria since it can only be seen under a microscope. The need for hematuria treatment has increased as the incidence of chronic renal disease and urinary tract infections has increased. Many tests, such as screening for sugar (diabetes), germs (infection), and blood, are performed on a regular basis. Blood can be detected with a chemical strip (also known as a dipstick) or under a microscope.
Key factors that are driving the growth of this market are high prevalence of hematuria-associated indications and increasing awareness about treatment options and improving healthcare expenditure are expected to boost the market growth for the hematuria treatments over the years.
The CAGR value of the hematuria treatments market during the forecasted period of 2021-2028 is 2.4%.
The drugs segment held the largest share of the market in the global hematuria treatments market and held the largest market share of 56.99% in 2020.
The urinary tract infections segment dominated the global hematuria treatments market and accounted for the largest market share of 17.31% in 2020.
The macroscopic hematuria segment dominated the global hematuria treatments market and held the largest market share of 48.04% in 2020.
The hospitals segment dominated the global hematuria treatments market and held the largest market share of 36.52% in 2020.
The hematuria treatments market majorly consists of the players such AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH among others.
The List of Companies - Hematuria Treatment Market
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Oct 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Oct 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Oct 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Oct 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Oct 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Oct 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)